Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > COMMENTARY
COMMENTARY
- JMA Needs to Establish New Partnership with LDP
April 17, 2006
- COMMENTARY 4 articles
April 3, 2006
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- <COMMENTARY> New Dispensing Fees Nearly Decided
February 20, 2006
- Japan's Most Admired Pharma Companies P. Reed Maurer
February 20, 2006
- Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
February 13, 2006
- Requirements for External IRBs to Be Relaxed
February 13, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
February 6, 2006
- COMMENTARY 2 articles
January 30, 2006
- JPLA SEMINAR
January 30, 2006
- Maurer's Healthcare Insight (72)
January 30, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -2-
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
January 30, 2006
- From "Replacement" to "Addition": Prescription Form
January 23, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) -2-
January 23, 2006
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…